DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05887999

CompletedPhase 1

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

A Phase 1, Randomized, Placebo-Controlled, 2-Period, Cross-over, Double- Blind, Single-Dose Study to Evaluate the Effects of LY3532226 on Insulin- Induced Hypoglycemia in Participants With Type 1 Diabetes Mellitus

Asset

Macupatide

Subcutaneous · GIP agonist

Listed sites

1

Recruiting sites

—

Enrollment

30

actual

Study population

Type 1 diabetes

Key I/E criterion

•BMI 18.5-40

Primary endpoint

•Pharmacodynamics (PD)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05887999
Org study ID18064
Secondary IDJ2V-MC-GZLCEli Lilly and Company

Timeline

Milestones

Study first posted2023-06-05actual
Study start2023-06-12actual
Primary completion2024-02-21actual
Study completion2024-02-21actual
Last update posted2024-03-26actual

Assets

Investigational agents

Macupatide

Study populations

Who this study enrolls

Type 1 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
•Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
•Are males or females not of childbearing potential

Exclusion criteria

•Have acute proliferative retinopathy requiring active treatment within 3 months of screening
•Have been treated with dipeptidyl peptidase-Ni, GLP-1 receptor agonists, GIP agonists, metformin or sodium-glucose cotransporter 2 inhibitors within the previous 3 months
•Have received systemic or inhaled glucocorticoid therapy
•Women of childbearing potential
•Are currently taking part in another clinical study trial involving medical research, or have participated within the last 30 days of screening in a clinical study involving a study intervention

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Other (unclassified)
2

Glycemic / diabetes

2 endpoints
Secondary/protocol endpoint/low confidence

The amount of exogenous glucose infused to maintain a plasma glucose level of >2.5 millimole per liter (mmol/L), after the insulin infusion is terminated.

Time frame:Predose up to 120 mins postdose

descriptive

Secondary/protocol endpoint

Change from Baseline in Fasting and Post meal Glucose during Standardized Mixed-meal Tolerance Test (sMMTT)

Time frame:Predose up to 120 mins postdose

Postprandial glucose

change from baseline, improvement

componentsFasting glucose, change, Postprandial glucose

Other (unclassified)

2 endpoints
Primary/protocol endpoint

Pharmacodynamics (PD): Area under the concentration versus time curve from time 60 to 120 minutes (AUC60-120min) of plasma glucagon during the insulin-induced hypoglycemia

Time frame:Predose up to 120 mins postdose

concentration, descriptive

Secondary/protocol endpoint/low confidence

Change from Baseline in Glucagon Concentration at Fasting and Post meal during sMMTT

Time frame:Predose up to 120 mins postdose

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.